So, Regeneron's price-to-earnings ratio [TTM] is 14.76x, which is not only 11.2% lower than its 5-year average but also lower than many of its peers, including AbbVie (ABBV) [P/E ratio is 19.06x ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

The board estimated that there would be a roughly 2% tax levy, or increase ... The district also used the board meeting to celebrate its Regeneron Science Talent Search finalist, Sandeep Sawhney ...

The French pharma group insists however that the move doesn’t signal any ... 20.6% stake in Regeneron, and has said it will shed around 12.8 million shares out of its current 23.2 million ...

All three drugs are being positioned as an off-the-shelf alternative to CAR-T therapies ... as well as a phase 1/2 trial (LINKER-MM4) in previously untreated patients. For Regeneron, linvoseltamab ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

sending its shares up 2.2% premarket. Regeneron beats quarterly estimates on eczema drug demand; launches dividend program Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Filled with the top stories to start your day, and emergency news alerts.

Car insurance can be a big expense these days: The average cost of a full coverage policy is $2,670 a year, according to Bankrate. That's up from $2,543 in February 2024 and $2,018 in February 2023.